Consumer group challenges Gilead patents on hepatitis C drug

Reuters

Media Article 25 Oct 2017

The New York City-based Initiative for Medicines, Access & Knowledge (I-MAK) asked the PTO’s Patent Trial and Appeal Board to invalidate six Gilead patents covering Sovaldi’s active ingredient and structure, saying they describe obvious tweaks to existing compounds used in older HIV and cancer drugs.

Join us to stay updated
and help make lifesaving medicines accessible to all